Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VRC-HIVDNA006-00-VP
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
**VRC-HIVDNA006-00-VP** is an investigational multiclade HIV-1 DNA plasmid vaccine developed by the National Institute of Allergy and Infectious Diseases Vaccine Research Center for prevention of HIV-1 infection. The vaccine encodes HIV-1 Gag, Pol, Nef, and Env antigens; after intramuscular administration, host cells express these antigens to induce HIV-specific cellular and humoral immune responses without exposing recipients to infectious HIV. It was evaluated in a randomized Phase 1 study in uninfected adults at 2 mg, 4 mg, and 8 mg dose levels, administered monthly for three doses by needle-free intramuscular injection. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00045838))
- Other names
- HIV-1 DNA plasmid vaccineHIV1 DNA plasmid vaccineHIV 1 DNA plasmid vaccineMulticlade HIV-1 DNA Plasmid Vaccine
02
Targets
Gag (HIV-1 Gag polyprotein)Human immunodeficiency virus type 1 reverse transcriptasegp41 (Human immunodeficiency virus type 1 glycoprotein 41)Nef (Protein Nef (Human immunodeficiency virus type 1))
Beyond the preview
Go deeper on VRC-HIVDNA006-00-VP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VRC-HIVDNA006-00-VP.